Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis

Gough, A L; Long, Richard; Cooper, Barrett R.; Fosters, C S; Garrett, Anna D.; Langworthy, C H

doi:10.1046/j.1365-2036.1996.14156000.x

Cited by 85 publications

(56 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both the extent and duration of symptomatic relief and the requirement for rescue GelusilÒ were significantly better with lansoprazole than ranitidine. Similarly, another study comparing lansoprazole and ranitidine for the maintenance of the healing of EE showed that lansoprazole-treated patients experienced significantly less heartburn and episodes of regurgitation than ranitidine-treated patients [19]. Studies comparing other PPIs and ranitidine for the symptomatic control of EE have also found superior symptom control with PPIs compared to H 2 RAs [21][22][23].…”

Section: Discussionmentioning

confidence: 94%

“…Another study compared lansoprazole and ranitidine in the maintenance of the healing of EE using a healing (rather than maintenance) dose of ranitidine (300 mg twice daily) [19]. This study showed that lansoprazole at daily doses of 30 or 15 mg was more effective than ranitidine 300 mg twice daily with respect to the time to endoscopic relapse (P B 0.001).…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

et al. 2008

View full text Add to dashboard Cite

In a study evaluating the efficacy and safety of lansoprazole to prevent the relapse of erosive esophagitis (EE), 206 of 241 patients (85%) healed after open-label treatment with lansoprazole 30 mg once daily for 8 weeks and received double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily for up to 1 year. At 1 year, 67% of lansoprazole-treated and 13% of ranitidine-treated patients remained healed (P<0.001). Lansoprazole-treated patients experienced significantly greater symptom relief (P<0.001), and, if asymptomatic at entry into the maintenance phase, remained asymptomatic for significantly longer than ranitidine-treated patients (P<0.001). Symptom status correlated with healing (P=0.001), supporting the symptom-directed management of EE. Both treatments were well tolerated and no unexpected events occurred. Daily therapy with lansoprazole to prevent the relapse of EE is effective, well tolerated, and superior to ranitidine in the maintenance of healing and symptom relief.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 95%

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Cimetidine 400 mg four times a day did not affect the frequency of the need for dilation (88), but several studies have found that fulldose PPIs will lengthen the interval between symptomatic relapses (89,90). There are no similar data in regards to the prevention or prevention of progression of Barrett's esophagus.…”

Section: Because Gerd Is a Chronic Condition Continuous Therapy To Cmentioning

confidence: 85%

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

DeVault¹

1999

The American Journal of Gastroenterology

143

178

View full text Add to dashboard Cite

PREAMBLEGuidelines for the diagnosis and treatment of gastroesophageal reflux disease (GERD) were published by the American College of Gastroenterology in 1995 (1). These and other guidelines undergo periodic review. Significant advances have been made in the area of GERD over the past several years, leading us to review and revise our previous guidelines statements. These advances have included an increase in our comfort with the chronic use of proton pump inhibitors and an increased acceptance of laparoscopic antireflux surgery, among other factors. These and the original guidelines are intended to apply to all physicians who address GERD and are intended to indicate the preferable, but not only acceptable, approach. Physicians must always choose the course best suited to the individual patient and the variables that exist at the moment of the decision. These guidelines are intended to apply to adult patients with the symptoms, tissue damage, or both that result from the reflux of gastric contents into the esophagus. For the purpose of these guidelines GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus.Both these and the original guidelines were developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee, and approved by the Board of Trustees. The world literature was reviewed extensively for the original guidelines and was once again reviewed using the National Library of Medicine database. All appropriate studies were reviewed and any additional studies found in the reference list of these papers were obtained and reviewed. Evidence was evaluated along a hierarchy, with randomized controlled trials given the greatest weight. Abstracts presented at national and international meetings were only used when unique data from ongoing trials were presented. When scientific data were lacking, recommendations were based on expert consensus. During preparation, the guidelines were reviewed

show abstract

“…Thus, comparative studies have demonstrated that protonpump inhibitors provided far superior GERD healing compared with histamine H 2 -receptor antagonists (H 2 -RAs). [1][2][3][4][5][6][7][8][9][10][11] In Japan, omeprazole 10 mg, as well as 20 mg, is widely used as maintenance therapy for GERD. Hallerback et al reported that maintenance therapy with omeprazole 10 mg was superior to ranitidine 300 mg 5 .…”

Section: Introductionmentioning

confidence: 99%

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H₂‐receptor antagonist

Shimatani

Inoue

Kuroiwa

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Omeprazole 10 mg is used as maintenance therapy for gastro-oesophageal reflux disease, but previous reports have not mentioned the potency of its acid suppression. Aim: To evaluate the potency of acid suppression with omeprazole 10 mg, in relation to CYP2C19 genotypes. Methods: Eighteen healthy subjects without Helicobacter pylori participated. After a 7-day regimen of omeprazole 10 mg, 20 mg, lafutidine 20 mg (a novel H 2 -receptor antagonist) or water only (baseline data), intragastric pH was measured for 24 h. Results: With omeprazole 10 mg, greater differences were observed than 20 mg in median pH values and pH > 4 holding time ratios between poor metabolizers (PMs, n ¼ 6) and the others [homozygous extensive metabolizers (homo-EMs, n ¼ 6) and heterozygous extensive metabolizers (hetero-EMs, n ¼ 6)]. With lafutidine 20 mg, these parameters were not influenced by the genotype. The potency of acid suppression was: omeprazole 20 mg lafutidine 20 mg > omeprazole 10 mg in homo-EMs, omeprazole 20 mg > omeprazole 10 mg lafutidine 20 mg in hetero-EMs, and omeprazole 20 mg omeprazole 10 mg > lafutidine 20 mg in PMs. Conclusions: Omeprazole 10 mg strongly suppresses acid secretion, but depending on the CYP2C19 genotypes shows greater interindividual variations in suppression than 20 mg.

show abstract

Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis

Abstract: Both lansoprazole 15 mg and lansoprazole 30 mg once daily are significantly more effective than high-dose ranitidine in maintaining reflux oesophagitis in remission.

Cited by 85 publications

References 0 publications

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H₂‐receptor antagonist

Contact Info

Product

Resources

About

Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis

Abstract: Both lansoprazole 15 mg and lansoprazole 30 mg once daily are significantly more effective than high-dose ranitidine in maintaining reflux oesophagitis in remission.

Cited by 85 publications

References 0 publications

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2‐receptor antagonist

Contact Info

Product

Resources

About

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H₂‐receptor antagonist